Mammalian target of rapamycin (mTOR), aging, neuroscience, and their association with aging-related diseases

Simple item page
buir.contributor.authorCelebi-Birand, Ergül Dilan
buir.contributor.authorKaroğlu, Elif Tuğçe
buir.contributor.authorDoldur-Ballı, Füsun
buir.contributor.authorAdams, Michelle M.
dc.citation.epage203en_US
dc.citation.spage185en_US
dc.contributor.authorCelebi-Birand, Ergül Dilanen_US
dc.contributor.authorKaroğlu, Elif Tuğçeen_US
dc.contributor.authorDoldur-Ballı, Füsunen_US
dc.contributor.authorAdams, Michelle M.en_US
dc.contributor.editorMaiese, K.
dc.date.accessioned2018-04-12T13:37:44Z
dc.date.available2018-04-12T13:37:44Z
dc.date.issued2016en_US
dc.departmentInterdisciplinary Program in Neuroscience (NEUROSCIENCE)en_US
dc.departmentDepartment of Molecular Biology and Geneticsen_US
dc.departmentDepartment of Psychologyen_US
dc.departmentAysel Sabuncu Brain Research Center (BAM)en_US
dc.descriptionChapter 11
dc.description.abstractNormal aging is accompanied by cognitive impairment with subtle cellular and molecular changes in the brain, whereas, pathological brain aging manifests as severe behavioral impairments with cellular pathology. Understanding the factors that contribute to both states is undoubtedly important for determining appropriate interventions that alter their progression. Mammalian target of rapamycin (mTOR) signaling has been implicated in affecting lifespan and age-related diseases such as cancer. The relationship of mTOR signaling with pathological brain aging has been more extensively studied, whereas the association with normal brain aging is not well understood. In this chapter we present information about normal and pathological brain aging, the relationship with mTOR signaling and use information from other age-related diseases to suggest that mTOR may have a role in promoting the cellular and molecular changes that underlie age-related cognitive changes. Future work should be directed towards understanding the precise role of mTOR signaling in brain aging. © 2016 Elsevier Inc. All rights reserved.en_US
dc.description.provenanceMade available in DSpace on 2018-04-12T13:37:44Z (GMT). No. of bitstreams: 1 bilkent-research-paper.pdf: 179475 bytes, checksum: ea0bedeb05ac9ccfb983c327e155f0c2 (MD5) Previous issue date: 2016en
dc.identifier.doi10.1016/B978-0-12-802733-2.00007-4en_US
dc.identifier.isbn9780128027332
dc.identifier.urihttp://hdl.handle.net/11693/37781
dc.language.isoEnglishen_US
dc.publisherElsevier Inc.en_US
dc.relation.ispartofMolecules to medicine with mTOR: translating critical pathways into novel therapeutic strategies
dc.relation.isversionofhttps://doi.org/10.1016/B978-0-12-802733-2.00007-4en_US
dc.relation.isversionofhttps://doi.org/10.1016/C2014-0-03321-7
dc.subjectAgingen_US
dc.subjectCognitive declineen_US
dc.subjectDementiaen_US
dc.subjectMetabolismen_US
dc.subjectMTORen_US
dc.subjectNeurodegenerative diseasesen_US
dc.subjectNeuronal cellsen_US
dc.subjectSynapsesen_US
dc.titleMammalian target of rapamycin (mTOR), aging, neuroscience, and their association with aging-related diseasesen_US
dc.typeBook Chapteren_US

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Mammalian_target_of_rapamycin(mTOR)_aging_neuroscience_and_their_association_with_aging_related-diseases.pdf
Size:
885.36 KB
Format:
Adobe Portable Document Format
Description:
Download

Collections

Scholarly Publications - BAM
Scholarly Publications - Molecular Biology and Genetics
Scholarly Publications - Psychology